Staging systems in AL amyloidosis
| . | Biomarker thresholds . | Staging . |
|---|---|---|
| 2004 Mayo stage with 2015 European modification of 2004 staging system32,33,38 | NT-proBNP ≥332 ng/L (or BNP ≥81) cTnT ≥0.035 ng/ml (or cTnI ≥0.1 or hsTnT ≥50) | Stage I: 0 markers above cutoff Stage II: 1 marker above cutoff Stage IIIa: both markers above cutoff and NT-proBNP <8500 (or BNP >700) Stage IIIb: both markers above cutoff and NT-proBNP ≥8500 (or BNP >700) |
| 2012 Mayo staging system34,38 | NT-proBNP ≥1800 ng/L (or BNP ≥800) cTNT ≥0.025 ng/ml (or hsTnT ≥40) dFLC ≥180 mg/L | Stage I: 0 markers above cutoff Stage II: 1 marker above cutoff Stage III: 2 markers above cutoff Stage IV: 3 markers above cutoff |
| 2014 Palladini renal staging system35 | eGFR ≤50 ml/min/1.73 m2 Proteinuria ≥5 g/24 h | Stage I: 0 thresholds met Stage II: either threshold met Stage III: both thresholds met |
| . | Biomarker thresholds . | Staging . |
|---|---|---|
| 2004 Mayo stage with 2015 European modification of 2004 staging system32,33,38 | NT-proBNP ≥332 ng/L (or BNP ≥81) cTnT ≥0.035 ng/ml (or cTnI ≥0.1 or hsTnT ≥50) | Stage I: 0 markers above cutoff Stage II: 1 marker above cutoff Stage IIIa: both markers above cutoff and NT-proBNP <8500 (or BNP >700) Stage IIIb: both markers above cutoff and NT-proBNP ≥8500 (or BNP >700) |
| 2012 Mayo staging system34,38 | NT-proBNP ≥1800 ng/L (or BNP ≥800) cTNT ≥0.025 ng/ml (or hsTnT ≥40) dFLC ≥180 mg/L | Stage I: 0 markers above cutoff Stage II: 1 marker above cutoff Stage III: 2 markers above cutoff Stage IV: 3 markers above cutoff |
| 2014 Palladini renal staging system35 | eGFR ≤50 ml/min/1.73 m2 Proteinuria ≥5 g/24 h | Stage I: 0 thresholds met Stage II: either threshold met Stage III: both thresholds met |
BNP, brain natriuretic peptide; cTnT, cardiac troponin T; cTnI, cardiac troponin I; hs-TnT, high-sensitivity cTnT; dFLC, difference between involved and uninvolved free light chain; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal of propedtide of BNP.